Sangamo completes acquisition of TxCell

04-Dec-2018 - Sangamo Therapeutics, Inc. announced the completion of the acquisition of TxCell, SA. TxCell is now a subsidiary of Sangamo and has been delisted from the French stock market. “The acquisition of TxCell immediately positions Sangamo as the leader in CAR-Treg development,” said Sandy Macrae, CEO ...

Sangamo Therapeutics to acquire TxCell

24-Jul-2018 - Sangamo Therapeutics and TxCell announced that they have entered into a definitive agreement on July 20, 2018 pursuant to which Sangamo will, following the completion of the contemplated acquisition of a majority stake of TxCell, file a simplified cash tender offer for the purchase of all then ...

TxCell receives Fast Track Designation from FDA for Ovasave

TxCell’s lead product designated for the treatment of moderate to severe Crohn’s disease

29-Jul-2015 - TxCell SA announced that the United States Food and Drug Administration (FDA) has granted Fast Track Designation to TxCell’s lead product Ovasave(R) for the treatment of moderate to severe Crohn’s disease. Ovasave already has an active IND (Investigational New Drug) with the FDA. The FDA Fast ...

TxCell raises approx. EUR 8 million through a private placement of 10 percent of its common shares

24-Jul-2015 - TxCell SA announced the successful completion of a private placement of a total amount of approximately EUR 8 million.“We are extremely pleased to welcome on board new, mostly international, institutional investors, as shareholders. Whilst TxCell operates in a mainstream technology, cellular ...

TxCell announces a temporary partial hold of activities at its pilot manufacturing unit

25-Jun-2015 - TxCell SA announced that it has temporarily put its pilot manufacturing facility activities at Besançon, France on partial hold. The decision was made in agreement with the French regulator, Agence Nationale de Sécurité du Médicament, (ANSM).The decision was made so that TxCell could take action ...

TxCell appoints Chief Executive Officer

29-Apr-2015 - TxCell SA announces the appointment of Stéphane Boissel as Chief Executive Officer (CEO). In addition, Dr. Miguel Forte, previously SVP Clinical and Regulatory, is promoted to Chief Operating Officer. Stéphane Boissel succeeds Damian Marron, who has resigned from the company to pursue other ...

TxCell receives EU Orphan Drug Designation for Col-Treg in the treatment of non-infectious uveitis

22-Dec-2014 - TxCell SA announced that the European Commission (EC) has granted orphan drug designation to TxCell's investigational medicinal product Col-Treg, a personalized T cell immunotherapy using collagen-II specific regulatory T-cells, for the treatment of autoimmune uveitis."Obtaining orphan drug ...

TxCell announces start of phase IIb clinical trial with Ovasave for refractory Crohn’s disease

05-Dec-2014 - TxCell SA announced that it has enrolled the first patient in its phase IIb clinical trial of its lead product Ovasave(R) in refractory Crohn’s disease. TxCell has received approval for this multi-center, multinational trial from the regulatory authorities in all six European countries in which ...

TxCell achieves positive results for Col-Treg in a model of autoimmune uveitis

30-Oct-2014 - TxCell SA announced that TxCell researchers have achieved positive results for Col-Treg, its second product candidate from its ASTrIA platform, in a model of autoimmune uveitis, a leading cause of blindness with very limited treatment options. TxCell demonstrated clear efficacy and tolerability ...

TxCell to lead POSITIVE project to automate first production step of Ovasave personalised cellular immunotherapy

Grant of over EUR 400,000 awarded by the Conseil Régional Provence-Alpes-Côte-D’azur to the consortium of TxCell, Gene and Cell therapy Unit, Nice (UTCG) and Biosafe

07-Jul-2014 - TxCell SA announced the launch of, and funding awarded to, the POSITIVE project in collaboration with the Gene and Cell therapy Unit (UTCG)developing new antiviral cell-based immunotherapiesand Biosafe, a Swiss private company, a developer of innovative solutions for cell processing. The ...